Zoetis Inc. (NYSE:ZTS) Shares Purchased by Cabot Wealth Management Inc.

Cabot Wealth Management Inc. increased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,693 shares of the company's stock after purchasing an additional 2,210 shares during the period. Cabot Wealth Management Inc.'s holdings in Zoetis were worth $10,652,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Rakuten Securities Inc. lifted its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 166 shares during the period. Navigoe LLC acquired a new stake in shares of Zoetis in the 4th quarter worth $30,000. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis in the 4th quarter worth $44,000. Sound Income Strategies LLC lifted its stake in shares of Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after acquiring an additional 164 shares during the period. Finally, Bfsg LLC lifted its stake in shares of Zoetis by 614.6% in the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after acquiring an additional 252 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 1.4%

Shares of NYSE ZTS opened at $157.26 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The firm has a 50-day moving average price of $159.58 and a 200 day moving average price of $163.40. The stock has a market capitalization of $70.01 billion, a price-to-earnings ratio of 28.23, a price-to-earnings-growth ratio of 2.57 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter last year, the business earned $1.38 earnings per share. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.27%. Zoetis's dividend payout ratio (DPR) is currently 35.91%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president now directly owns 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.18% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a research note on Wednesday. UBS Group reduced their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Finally, Piper Sandler raised their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of "Buy" and a consensus price target of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.